Latest Celgene Corp (CELG) Headlines 'Fast Money' Recap:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Celgene Corp (CELG) Headlines

'Fast Money' Recap: From Stocks to Bonds?
at The Street - 1 hr 32 mins ago
The trading panel discussed the S&P 500, copper and emerging markets.

Final Glance: Biotechnology companies
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

Midday Glance: Biotechnology companies
AP - Wed Mar 12, 12:28PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:

Early Glance: Biotechnology companies
AP - Wed Mar 12, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Has Celgene Corporation Run Out of Steam in 2014?
Peter Stephens, The Motley Fool - Motley Fool - Sun Mar 09, 6:00AM CDT
Last year was a fantastic one for  Celgene    shareholders. Shares rose by 117% -- easily beating the S&P 500, which still managed to post a very respectable gain of just under 32%. Furthermore, Celgene was able to beat two of its biotechnology...

Watch for Shares of Celgene (CELG) to Approach Support at $149.77
Comtex SmarTrend(R) - Fri Mar 07, 9:35AM CST
Celgene (NASDAQ:CELG) has opened bearishly below the pivot of $159.20 today and has reached the first level of support at $153.19. Analysts will be watching for a cross of the next downside pivot targets of $149.77 and $140.34.

Stocks Open Higher, Turn Mixed After Employment Report
at Investor's Business Daily - Fri Mar 07, 9:31AM CST
Stocks opened higher Friday, then backtracked to mixed terrain as drugmakers and some leading stocks added drag in early trade. The Dow Jones industrial average remained ahead 0.4%. The S&P 500 was up 0.2% and the Nasdaq slipped 0.2%. Celgene (CELG),...

Celgene Set to Possibly Rebound After Yesterday's Selloff of 4.06%
Comtex SmarTrend(R) - Thu Mar 06, 4:02PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $155.78 to a high of $165.21. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $158.63 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

SmarTrend Watching for Potential Rebound in Shares of Celgene After 4.06% Loss
Comtex SmarTrend(R) - Thu Mar 06, 4:01PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $155.78 to a high of $165.21. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $158.63 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Better Biotech Buy: Celgene vs. Gilead Sciences
Dan Carroll, The Motley Fool - Motley Fool - Thu Mar 06, 1:30PM CST
Big biotech stocks have been on a roll lately, and industry mainstays Celgene and Gilead Sciences are no exceptions. Each stock has gained more than 50% over the past year as these two companies surge behind older established cash cow drugs...

Celgene Corporation (CELG) Stock Research Links

CELG Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Perrigo's Reinvention Strategy: A Path to Sustainable Success

Updated Category News Views 152

Perrigo Restructures for Future Growth and Performance Perrigo Company plc (NYSE: PRGO), a recognized leader in the consumer self-care products industry, has embarked on an ambitious path of organizational realignment aimed at ensuring sustainable growth and enhanced operational performance. This strategic initiative is expected to bolster agility and innovation within...

Continue Reading
Eli Lilly Prepares for Weight-Loss Drug Launch Amid FDA Review

Updated Category News Views 225

Eli Lilly's Strategic Inventory Build-Up Eli Lilly and Company (NYSE: LLY) has made headlines recently by accumulating an impressive $1.5 billion worth of inventory for its experimental oral weight-loss pill, orforglipron. This move comes in light of the anticipated decision by the FDA, which could take place in the near future. The increase in inventory value represents...

Continue Reading
Roblox's CFO Transition: Leadership Change and Future Prospects

Updated Category News Views 352

Roblox Corporation Announces CFO Transition Roblox Corporation (NYSE:RBLX) has recently made headlines as its Chief Financial Officer, Michael Guthrie, prepares to leave his post to focus on personal pursuits. This change reflects a significant moment in the company's leadership dynamics, with the announcement stemming from a formal Separation and Transition Agreement....

Continue Reading
MaxCyte's 2024 Financial Results Highlight Growth and Innovation

Updated Category News Views 149

MaxCyte Reports Positive Financial Results for 2024 MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a renowned company at the forefront of cell engineering, has shared exciting preliminary financial outcomes for its fourth quarter and the entire year of 2024. These results demonstrate steady growth in revenue and a stronger position in the rapidly evolving cell therapy industry....

Continue Reading
XORTX Therapeutics Invites Shareholders to Participate Actively

Updated Category News Views 113

XORTX Therapeutics Encourages Shareholder Participation CALGARY, Alberta – XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a leading clinical pharmaceutical company focused on developing innovative therapies for progressive kidney disease, is reaching out to its shareholders. They want to remind everyone about the important voting deadline for the...

Continue Reading